Health Care
Radiopharm Theranostics Limited (RAD)
Radiopharm Theranostics Limited (ASX: RAD), listed in November 2021, operates in the Health Care sector focusing on Pharmaceuticals, Biotechnology, and Life Sciences. They are developing targeted theranostic products for cancer treatment, primarily working in Australia with potential for global market expansion. Key products/services include radiopharmaceuticals for both diagnostic imaging and targeted cancer therapy.
Market Cap
A$78M
Shares on Issue
N/A
Price Chart
AI Analysis
As a recent ASX debutant with a market cap of A$78M, RAD is in an early development stage, characteristic of high-risk, high-reward biotech investments. Recent performance may reflect listing adjustments and initial operational setup. Key metrics to watch include R&D expenditure, partnership announcements, and clinical trial timelines.
Growth prospects hinge on successful clinical trials, strategic partnerships, and regulatory approvals. Upcoming catalysts might include Phase I/II trial results for lead compounds, collaborations with larger pharmaceutical firms, or expansion into new therapeutic areas.
Bull Case
- • Successful Phase II clinical trial results for a lead radiopharmaceutical candidate, leading to significant partnership interest or valuation boost
- • Strategic partnership with a global pharmaceutical company for development and commercialization, providing financial and technical validation
- • Approval for a diagnostic imaging product in a major market (e.g., Australia, US, EU), generating early revenue streams
Bear Case
- • Unfavorable results from critical clinical trials, halting development of a key asset and impacting investor confidence
- • Intense competition from established biotech firms with more advanced theranostic pipelines, limiting RAD's market share potential
- • Significant dilution from repeated capital raisings to fund lengthy and costly clinical development phases
Recent Announcements
Quarterly Activities/Appendix 4C Cash Flow Report
🚨 Price SensitiveRad Ltd, a commitments test entity on ASX, has reported its quarterly cash flow activities in Appendix 4C of the latest financial documents. Investors should review these details to assess Rad's liquidity and capital allocation strategies for this period.
RAD Increases Ownership in Radiopharm Ventures to 87.5%
Change in substantial holding
FAQs
What does RAD do?
RAD develops targeted theranostic products (diagnostics and therapies) using radiopharmaceuticals, primarily for cancer treatments.
Is RAD a good investment?
RAD offers high growth potential due to its innovative approach, but as a small-cap biotech, it comes with high risk due to clinical trial uncertainties and capital requirements.
What drives RAD's share price?
Key drivers include clinical trial outcomes, strategic partnerships, regulatory approvals, and the overall biotech sector sentiment on the ASX.
Key Metrics
Related Stocks
Health Care
CSLCSL Ltd
A$181.24
-27.3% 1Y
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Health Care
PNVPolynovo Ltd
A$0.99
-13.1% 1Y
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Health Care
1ADAdalta Limited
A$0.01
-25.6% 1Y
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.